Bolt Biotherapeutics' GAAP loss for 9M 2021 was $71.434 million, up 2.4 times from $29.693 million in the previous year. Revenue increased 3.3-fold to $752,000 from $231,000 a year earlier.
Bolt Biotherapeutics' GAAP loss for 9M 2021 was $71.434 million, up 2.4 times from $29.693 million in the previous year. Revenue increased 3.3-fold to $752,000 from $231,000 a year earlier. 
investors.boltbio.com
English (US) 